Title
Category
Credits
Event date
Cost
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  • 0.75 ACPE ...See more
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).